ZA200402687B - Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors - Google Patents
Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors Download PDFInfo
- Publication number
- ZA200402687B ZA200402687B ZA2004/02687A ZA200402687A ZA200402687B ZA 200402687 B ZA200402687 B ZA 200402687B ZA 2004/02687 A ZA2004/02687 A ZA 2004/02687A ZA 200402687 A ZA200402687 A ZA 200402687A ZA 200402687 B ZA200402687 B ZA 200402687B
- Authority
- ZA
- South Africa
- Prior art keywords
- approximately
- administering
- milligrams
- composition
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 101
- 239000000203 mixture Substances 0.000 title claims description 65
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N (+)-Erythro-hydroxycitric acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 title claims description 64
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title claims description 42
- 229910052804 chromium Inorganic materials 0.000 title claims description 42
- 239000011651 chromium Substances 0.000 title claims description 42
- 229930183009 gymnemic acid Natural products 0.000 title claims description 31
- 230000037396 body weight Effects 0.000 title claims description 22
- 230000036541 health Effects 0.000 title description 7
- 230000001737 promoting effect Effects 0.000 title description 4
- ZMJBYMUCKBYSCP-AWFVSMACSA-N (1s,2r)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-AWFVSMACSA-N 0.000 title description 3
- 241000196324 Embryophyta Species 0.000 claims description 33
- 241000124008 Mammalia Species 0.000 claims description 30
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 26
- 241000593508 Garcinia Species 0.000 claims description 18
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims description 18
- 102000016267 Leptin Human genes 0.000 claims description 17
- 108010092277 Leptin Proteins 0.000 claims description 17
- 229940039781 leptin Drugs 0.000 claims description 17
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000037406 food intake Effects 0.000 claims description 12
- 235000012631 food intake Nutrition 0.000 claims description 12
- 229940076279 serotonin Drugs 0.000 claims description 12
- 235000012054 meals Nutrition 0.000 claims description 10
- 230000036528 appetite Effects 0.000 claims description 9
- 235000019789 appetite Nutrition 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 4
- 238000008214 LDL Cholesterol Methods 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 229940089491 hydroxycitric acid Drugs 0.000 claims 31
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 16
- 229960003512 nicotinic acid Drugs 0.000 claims 16
- 235000001968 nicotinic acid Nutrition 0.000 claims 16
- 239000011664 nicotinic acid Substances 0.000 claims 16
- 239000002253 acid Substances 0.000 claims 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 8
- 241000208251 Gymnema Species 0.000 claims 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 8
- 239000011575 calcium Substances 0.000 claims 8
- 229910052791 calcium Inorganic materials 0.000 claims 8
- 239000011591 potassium Chemical group 0.000 claims 8
- 229910052700 potassium Chemical group 0.000 claims 8
- 241000208253 Gymnema sylvestre Species 0.000 claims 7
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000018770 reduced food intake Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003925 fat Substances 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 14
- 235000020824 obesity Nutrition 0.000 description 13
- 206010033307 Overweight Diseases 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004132 lipogenesis Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000218671 Ephedra Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000020595 eating behavior Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000020881 DASH diet Nutrition 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000000775 effect on neurotransmitter Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34347301P | 2001-12-20 | 2001-12-20 | |
| PCT/US2002/041171 WO2003053454A1 (en) | 2001-12-20 | 2002-12-20 | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402687B true ZA200402687B (en) | 2005-02-23 |
Family
ID=23346261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2004/02687A ZA200402687B (en) | 2001-12-20 | 2004-04-06 | Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US20030119913A1 (https=) |
| EP (1) | EP1461051A1 (https=) |
| JP (1) | JP2005513107A (https=) |
| AU (1) | AU2002364213B2 (https=) |
| CA (1) | CA2463427A1 (https=) |
| IL (1) | IL161212A0 (https=) |
| MX (1) | MXPA04006166A (https=) |
| NZ (1) | NZ532550A (https=) |
| WO (1) | WO2003053454A1 (https=) |
| ZA (1) | ZA200402687B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927636B1 (en) | 1997-07-14 | 2011-04-19 | Interhealth Nutraceuticals, Inc. | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US6503905B1 (en) * | 1998-12-29 | 2003-01-07 | Pfizer Inc | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| US7119110B2 (en) * | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| ES2283756T3 (es) * | 2002-03-01 | 2007-11-01 | Novagali Pharma Sa | Sistemas autoemulsionantes de administracion de farmaco para taxoides. |
| US8394856B2 (en) * | 2002-07-02 | 2013-03-12 | Glykon Technologies Group, Llc | (-)-Hydroxycitric acid for controlling inflammation |
| JP2004181452A (ja) * | 2002-11-30 | 2004-07-02 | Matsushita Electric Ind Co Ltd | 洗浄装置、洗浄方法および洗浄剤 |
| TW200427447A (en) * | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
| US20050009919A1 (en) * | 2003-07-07 | 2005-01-13 | Clouatre Dallas L. | Treating cachexia and excessive catabolism with (-)-hydroxycitric acid |
| US20050053555A1 (en) * | 2003-07-14 | 2005-03-10 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| US20050215644A1 (en) * | 2004-03-19 | 2005-09-29 | Interhealth Nutraceuticals, Inc. | Methods for increasing neurotransmitter levels using hydroxycitric acid |
| WO2005107735A2 (en) | 2004-04-30 | 2005-11-17 | Pump Formulations, Ltd. | Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a |
| JP2007535576A (ja) * | 2004-04-30 | 2007-12-06 | ニュー・エイチ・シー・フォーミュレーションズ・リミテッド | 迅速な体重減少を促進し、カロリーを燃焼させ、熱発生を増大させ、エネルギー代謝を補助し、且つ／または食欲を抑制する栄養組成物 |
| US20060025483A1 (en) * | 2004-07-29 | 2006-02-02 | Clouatre Dallas L | (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification |
| EP1799631B1 (en) * | 2004-09-24 | 2017-01-25 | Showa Denko K.K. | Hydroxycitric acid derivatives and skin external preparations containing the same |
| EP1827139A2 (en) * | 2004-12-14 | 2007-09-05 | Lean Balance Formulations Ltd. | Supplement dietary composition for promoting weight loss |
| US7912716B2 (en) * | 2005-10-06 | 2011-03-22 | Sony Online Entertainment Llc | Generating words and names using N-grams of phonemes |
| WO2008048574A2 (en) * | 2006-10-18 | 2008-04-24 | Dallas Clouatre | Hca for improved hdl serum lipids profile |
| US20100323031A1 (en) * | 2009-06-22 | 2010-12-23 | Glykon Technologies Group, Llc | Synergistic combination to enhance blood glucose and insulin metabolism |
| US20100323043A1 (en) * | 2009-06-23 | 2010-12-23 | Perla Marc D | Antimicrobial Compositions and Methods of Making and Using the Same |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| WO2012050895A1 (en) | 2010-09-28 | 2012-04-19 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| US20130059035A1 (en) * | 2011-09-07 | 2013-03-07 | Massoud Arvanaghi | Capsaicin composition and method related thereto |
| WO2018057737A1 (en) | 2016-09-22 | 2018-03-29 | Cash Alan B | Method to alleviate the symptoms of pms |
| CN110882390B (zh) * | 2019-11-15 | 2022-03-15 | 西安交通大学医学院第一附属医院 | 人lsm5基因的用途及相关产品 |
| US11766415B2 (en) * | 2020-06-02 | 2023-09-26 | Glykon Technologies Group, Llc | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US133992A (en) * | 1872-12-17 | Improvement in bed-lounges | ||
| US132219A (en) * | 1872-10-15 | Improvement in combined knife-sharpeners and glass-cutters | ||
| US14692A (en) * | 1856-04-15 | Improved diaphragm fluid-meter | ||
| US44469A (en) * | 1864-09-27 | Improved clothes-drier | ||
| US220329A (en) * | 1879-10-07 | Improvement in pounder washing-machines | ||
| US3764692A (en) * | 1970-09-30 | 1973-10-09 | Hoffmann La Roche | Method of treating obesity |
| US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
| US5194615A (en) * | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
| US4923855A (en) * | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
| JPS62236469A (ja) * | 1986-04-04 | 1987-10-16 | Yasutake Hichi | 低カロリ−飲食物 |
| US5266560A (en) * | 1988-06-03 | 1993-11-30 | Thomas Research Corporation | Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity |
| US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
| US5480657A (en) * | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
| US5612039A (en) * | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
| US5567424A (en) * | 1994-06-10 | 1996-10-22 | Reliv International, Inc. | Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption |
| US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
| US5536516A (en) * | 1994-08-24 | 1996-07-16 | Renaissance Herbs, Inc. | Hydroxycitric acid concentrate and food products prepared therefrom |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| WO1996036585A1 (en) * | 1995-05-15 | 1996-11-21 | Sabinsa Corporation | A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy citric acid |
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| IT1276253B1 (it) * | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi |
| US5716976A (en) * | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| FI120290B (fi) | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia |
| JP2001511153A (ja) * | 1997-02-04 | 2001-08-07 | ブイ． コスバブ，ジョン | 血管変性性疾患の予防および処置のための組成物および方法 |
| US5962030A (en) * | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
| JP3736776B2 (ja) | 1997-03-25 | 2006-01-18 | 宝ホールディングス株式会社 | 新規カルシウム組成物 |
| US5981510A (en) * | 1997-04-15 | 1999-11-09 | Yaizu Suisankagaku Industry Co., Ltd. | Method for treating and improving diabetes |
| US5911992A (en) * | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
| US7927636B1 (en) | 1997-07-14 | 2011-04-19 | Interhealth Nutraceuticals, Inc. | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US5877171A (en) * | 1997-07-28 | 1999-03-02 | Mcleod; Malcolm N. | Method of treating pre-menstrual syndrome using chromium |
| US6160172A (en) * | 1997-08-27 | 2000-12-12 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties |
| CA2320368C (en) * | 1998-02-23 | 2007-08-21 | Taiyo Kagaku Co., Ltd. | Composition comprising theanine |
| US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
| AU5142699A (en) * | 1998-07-31 | 2000-02-28 | Mount Sinai Hospital Corporation | Methods and compositions for increasing insulin sensitivity |
| US5905075A (en) * | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
| AU5802499A (en) * | 1998-09-01 | 2000-03-21 | Amway Corporation | Diet composition and method of weight management |
| US6252713B1 (en) * | 1998-10-28 | 2001-06-26 | Asahi Kogaku Kogyo Kabushiki Kaisha | Optical device provided with correcting function for trembling of focused image |
| WO2000048983A1 (en) | 1999-02-18 | 2000-08-24 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group ia and iia of (-) hydroxycitric acid |
| AU4326500A (en) | 1999-03-26 | 2000-10-16 | Akesis Pharmaceuticals, Inc. | Beverages for treatment of glucose metabolism disorders |
| US6207714B1 (en) * | 1999-09-14 | 2001-03-27 | Dallas L. Clouatre | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid |
| US6447807B1 (en) * | 1999-09-14 | 2002-09-10 | Dallas L. Clouatre | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery |
| US20030220329A1 (en) * | 1999-09-17 | 2003-11-27 | Duke University | Method of improving beta-adrenergic receptor function |
| WO2001043758A1 (en) * | 1999-12-16 | 2001-06-21 | Mark Nutritionals Inc | Nutritional composition, methods of producing said composition and methods of using said composition |
| US6291533B1 (en) * | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
| US7015250B2 (en) * | 2000-02-09 | 2006-03-21 | Glykon Technologies Group, Llc | Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid |
| US6399089B1 (en) * | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
| US6383482B1 (en) * | 2000-08-24 | 2002-05-07 | Vitacost.Com, Inc. | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
| CN1665566A (zh) * | 2000-09-21 | 2005-09-07 | 营养21公司 | 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物 |
| US6579866B2 (en) * | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
| US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
| US20020133992A1 (en) * | 2001-03-20 | 2002-09-26 | Julie Wu | Magnetic display device |
| AU2002305132B2 (en) * | 2001-03-30 | 2007-05-31 | Lonza Consumer Health Inc. | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid |
| US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| US6476071B1 (en) * | 2001-05-07 | 2002-11-05 | Dallas L. Clouatre | Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid |
| US6441041B1 (en) * | 2001-06-20 | 2002-08-27 | Dallas L. Clouatre | (-)-hydroxycitric acid for the prevention of osteoporosis |
| US6482858B1 (en) * | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
| US6638542B2 (en) * | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
| US7119110B2 (en) * | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| US7507421B2 (en) | 2002-04-30 | 2009-03-24 | Unibar Corporation | Hydroxycitric acid salt composition and method of making |
| US6967030B2 (en) * | 2003-01-14 | 2005-11-22 | Wright Jonathan V | Formulation for insulin and glucose control |
| TW200427447A (en) * | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
-
2002
- 2002-04-02 US US10/115,266 patent/US20030119913A1/en not_active Abandoned
- 2002-12-20 EP EP02799288A patent/EP1461051A1/en not_active Withdrawn
- 2002-12-20 JP JP2003554211A patent/JP2005513107A/ja active Pending
- 2002-12-20 CA CA002463427A patent/CA2463427A1/en not_active Abandoned
- 2002-12-20 IL IL16121202A patent/IL161212A0/xx unknown
- 2002-12-20 AU AU2002364213A patent/AU2002364213B2/en not_active Ceased
- 2002-12-20 NZ NZ532550A patent/NZ532550A/en not_active IP Right Cessation
- 2002-12-20 US US10/325,675 patent/US20040014692A1/en not_active Abandoned
- 2002-12-20 WO PCT/US2002/041171 patent/WO2003053454A1/en not_active Ceased
- 2002-12-20 MX MXPA04006166A patent/MXPA04006166A/es unknown
-
2004
- 2004-04-06 ZA ZA2004/02687A patent/ZA200402687B/en unknown
- 2004-08-03 US US10/911,181 patent/US20050008726A1/en not_active Abandoned
- 2004-08-03 US US10/911,180 patent/US20050008725A1/en not_active Abandoned
- 2004-08-03 US US10/911,095 patent/US7335651B2/en not_active Expired - Lifetime
- 2004-08-03 US US10/911,791 patent/US20050013887A1/en not_active Abandoned
- 2004-08-03 US US10/911,173 patent/US20050008724A1/en not_active Abandoned
- 2004-08-03 US US10/911,096 patent/US20050008723A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040014692A1 (en) | 2004-01-22 |
| US20050008725A1 (en) | 2005-01-13 |
| MXPA04006166A (es) | 2005-07-05 |
| US20050008724A1 (en) | 2005-01-13 |
| JP2005513107A (ja) | 2005-05-12 |
| EP1461051A1 (en) | 2004-09-29 |
| US20050013887A1 (en) | 2005-01-20 |
| WO2003053454A1 (en) | 2003-07-03 |
| CA2463427A1 (en) | 2003-07-03 |
| US20050008722A1 (en) | 2005-01-13 |
| US7335651B2 (en) | 2008-02-26 |
| US20030119913A1 (en) | 2003-06-26 |
| US20050008726A1 (en) | 2005-01-13 |
| AU2002364213B2 (en) | 2007-03-15 |
| US20050008723A1 (en) | 2005-01-13 |
| AU2002364213A1 (en) | 2003-07-09 |
| NZ532550A (en) | 2005-09-30 |
| IL161212A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200402687B (en) | Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
| US6413545B1 (en) | Diet composition and method of weight management | |
| MXPA04003233A (es) | Metodo y composicion para prevenir o reducir los sintomas del sindrome de resistencia a la insulina. | |
| EP1427297B1 (en) | Composition for reducing appetite in mammals comprising procyanidin | |
| MXPA06012501A (es) | Composicion nutricional que promueve la perdida de peso, quema calorias, aumenta la termogenesis, sustenta el metabolismo de la energia y/o suprime el apetito. | |
| US20040265398A1 (en) | Herbal composition for weight control | |
| DE19818563C2 (de) | Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung | |
| TW200304372A (en) | Compositions for diabetes | |
| CN109745359A (zh) | 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法 | |
| US20060269617A1 (en) | Supplement compositions and method of use for enhancement of insulin sensitivity | |
| US20050008712A1 (en) | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight | |
| US20100323031A1 (en) | Synergistic combination to enhance blood glucose and insulin metabolism | |
| AU2002305132B2 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
| US20030039708A1 (en) | Non-ma huang herb weight loss product | |
| KR100532556B1 (ko) | 솔잎, 녹차 및 홍차 추출물을 유효성분으로 함유하는 비만및 변비 치료용 조성물 | |
| PL207522B1 (pl) | Zastosowanie acetylo-L-karnityny w połączeniu z biotyną | |
| AU2007202775A1 (en) | Compositions incorporating (-)- hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
| US20080279968A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids | |
| CN121401381A (zh) | 一种改善肥胖和促进心血管健康的组合物及其制备方法与应用 | |
| US20230102471A1 (en) | Composition And Method for Modulating Hydrogen Ion Physiology Related to Weight Loss and Metabolism | |
| WO2003061679A1 (en) | Composition for blood sugar regulation | |
| An et al. | Regulatory effect of sense line diet on cholesterol and body weight in mice fed a high-fat diet | |
| US20130209379A1 (en) | Lip cosmetic formulations | |
| CA2588436A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids |